Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Year | Receivables | Debt | Liabilities | Assets | Current Assets |
---|---|---|---|---|---|
2023 | -37,216,000 | 78.61 M | 395.3 M | 320.68 M | |
2022 | -229,119,000 | 103.06 M | 514.91 M | 444.5 M | |
2021 | -341,696,000 | 44.89 M | 501.42 M | 420.02 M | |
2020 | -62,390,000 | 238.81 M | 124.83 M | 119.99 M | |
2019 | -25,894,000 | 69.12 M | 55.51 M | 51.12 M |